TribLIVE

| USWorld


 
Larger text Larger text Smaller text Smaller text | Order Photo Reprints

House GOP to FDA: Deliver documents on meningitis crisis

Daily Photo Galleries

By Reuters
Monday, Nov. 19, 2012, 8:02 p.m.
 

WASHINGTON — Republicans on a congressional panel investigating a deadly meningitis outbreak linked to tainted drugs have told the nation's top drug regulator not to expect new authority to prevent more problems until the agency hands over documents about its role in the crisis.

As the number of meningitis cases edged toward the 500 mark, the House of Representatives Energy and Commerce Committee's Republican majority staff released on Monday a letter that gave the Food and Drug Administration until the end of November to comply with a document request first made in mid-October.

“We need these documents to identify any possible weaknesses in FDA's regulatory system that can be immediately corrected administratively or legislatively,” said the letter, dated Nov. 16 and addressed to FDA Commissioner Margaret Hamburg by four Republicans.

“This committee has a long history of thoroughly and deliberatively investigating problems and offering solutions. We cannot and will not be in a position to do so in this case until we have a full accounting,” the letter said.

FDA officials had no comment.

The regulatory agency has asked lawmakers to clarify its authority to oversee large-scale drug compounders such as Massachusetts-based New England Compounding Center, the maker of epidural steroid injections that have been linked to a fungal meningitis outbreak that has now killed 33 people in 19 states.

Drug compounding is a longstanding practice in which pharmacists alter or recombine existing drugs to meet the special needs of specific patients. Some compounders have evolved into large-scale producers that experts say should be subject to FDA regulation.

State pharmacy boards are primarily responsible for oversight. FDA officials say their authority to oversee compounders has been challenged regularly in federal court, leading to conflicting rulings in different parts of the country.

A handful of House Democrats have called for congressional action to bring clarity to the situation before year end. But at a committee hearing on Nov. 14, several Republicans charged that FDA already had the authority to avoid the outbreak but failed to, despite repeated problems at NECC.

On Oct. 17 the committee submitted a bipartisan request for FDA documents relating to the outbreak including its dealings with NECC and the Massachusetts pharmacy board that was the primary regulator for NECC.

The latest letter to FDA contained no Democratic signatures.

Republicans said a similar request to Massachusetts health authorities produced thousands of internal state emails.

“FDA has provided the committee with zero. In fact, when asked by committee staff on Nov. 16, FDA staff stated that they had not even begun to search for responsive emails,” their letter said.

 

 
 


Show commenting policy

Most-Read Nation

  1. Florida man gets life in loud music killing
  2. Expert: Stress level rises for Americans who forfeit vacation
  3. If nurses in safety gear got Ebola ...
  4. ISIS lacks deadly chemical munitions in Iraq, Syria, Pentagon claims
  5. Obama expected to nominate ACLU lawyer Gupta for Justice civil rights division
  6. Global growth scare fells stocks as Dow Jones drops 460 points
  7. Wrongly convicted man freed after 28 years
  8. Open encrypted messages by updating technology access law, FBI Director Comey says
  9. From fringe of solar system, comet will streak by Mars, sun
  10. Resignation of Holder’s deputy to add to vacuum
  11. Riots shake Keene State College in New Hampshire
Subscribe today! Click here for our subscription offers.